(c) Cyclotek Queensland Pty Ltd validates 18F Florbetaben to support pharmaceutical sponsored clinical trials as a bio-market for therapeutic trials and supporting local researchers with their respective Investigator Sponsored Studies.

(d) Cyclotek NSW Pty Ltd acquires the business of PETTECH Solutions Pty Ltd with a commencement date of 2 January 2019. This acquisition enables the business to further develop PET Radiopharmaceuticals into the NSW marketplace.

2018

(1) Cyclotek New Zealand undertakes a technology transfer for the manufacture of 18F-DCFPyL a Prostate Specific Radiopharmaceutical. Supply commenced in June 17;

(3) At the request of Peter MacCallum and Genentech, Cyclotek undertakes a technology transfer for 18F FES for use in breast cancer monitoring;

(4) Cyclotek appoints Mr Doug Cubbin as an independent Director;

(5) Cyclotek, in conjunction with GE Healthcare and Macquarie University, has been awarded funding under the Commonwealth’s Cooperative Research Centres – Project (CRC-P) to conduct a clinical trial to evaluate 18F DCFPyL in comparison to WB Bone Scans and CT;

(1) Cyclotek QLD – Site validation completed, building certifier approved, QLD Health and TGA approval achieved by May 2016. Commenced commercial supply of FDG on 30 May 2016.
(2) 18F-DCFPyL in-licence agreement finalised with Johns Hopkins University for use of the F18 PSMA tracer for Prostate cancer for Australia and New Zealand.
(3) Cyclotek undertakes a development plan for the GMP manufacture of 18F-DCFPyL (Prostate Specific Radiopharmaceutical)

2016

Procure, Install and Commission of a GE PETTrace cyclotron with its support equipment together with Comecer hotcels and GE FASTlabs synthesis units into the new Victorian Comprehensive Cancer Centre

2015 - VCCC

(1) Cyclotek commenced site preparation work at the Princess Alexandra Hospital, building 39;

(2) Construction of the vault and laboratories with procurement of a GE self shielded PETTrace cyclotron with support equipment and supplies;

(3) Installation and commission of GE self shielded PETTrace cyclotron and support equipment and infrastructure.

2015 - PAH

(1) On request from clinicians, Cyclotek validates the GMP production of FCH;
(2) GE Healthcare and Cyclotek sign Statement of Work for the evaluation of stability of the Nb targets for the MINItrace at 70µA;
(3) Increase capacity of PETtrace cyclotron from 100µA to130µA.

2014

On request from clinicians, Cyclotek validates the GMP production of FLT;

2013

Cyclotek completes seven year participation in the CRC for Biomedical Imaging Development Ltd.

2012

(1) On request from clinicians, Cyclotek validates the GMP production of NaF;
(2) GE Healthcare and Cyclotek sign Statement of Work for the evaluation of Niobium (Nb) targets for the MINItrace.

2011

(1) On request from clinicians, Cyclotek validates the GMP production of FET;
(2) Cyclotek participates in clinical trial of PET tracer MEL050, for CRC for Biomedical Imaging Development. The purpose of this study is to investigate the safety and potential effectiveness of MEL050 for metastatic melanoma.

2010

(1) Cyclotek, along with our JV partners (Pacific Radiology Group), established Cyclotek Pharmaceuticals Ltd (CPL) company in New Zealand. GE Healthcare was again selected to supply, install and commission a PETtrace 10Ci cyclotron, our third cyclotron into the group;

(2) Cyclotek is engaged by Pharma to manufacture Amyloid PET tracers under contract for clinical trials.

2009

Increase capacity of PETtrace cyclotron from 70µA to 100µA.

2008

Installation of second cyclotron in the Bundoora facility, a GE MINItrace.

Initiate research project for the automation of FET synthesis in collabaration with Peter MacCallum Cancer Centre.

2004

Site design, build and commissioning of Cyclotek’s first PET Radiopharmaceutical facility, with a GE PETtrace 6Ci cyclotron with support infrastructure and equipment. Supply FDG into Australian marketplace.

2002

Business case for the establishment of Australia’s first commercial medical cyclotron.